Amino Acid Quantitative Analysis
Disclaimer: This work has been submitted by a student. This is not an example of the work written by our professional academic writers. You can view samples of our professional work here.
Any opinions, findings, conclusions or recommendations expressed in this material are those of the authors and do not necessarily reflect the views of UK Essays.
Published: Thu, 24 May 2018
Amino acids give the basic building blocks of forming a protein and play an essential role in the energy metabolism, neurotransmission, and lipid transport. Their quantitative analysis is important for various uses, including disease diagnostics and in elucidating nutritional influences on physiology (Fromm & Hargrove, 2012).
Amino acid levels in the body fluids are used to diagnose metabolic deficiencies. Deprived or excessive levels of amino acids can show different defects of deficiencies (Lanpher, 2006). Preparation requirements and sample clean-up make the procedure a slow procedure. While some protocols may provide adequate chromatographic methods and derivatization procedures, that makes it more sufficient and quicker.
Leucine is an essential amino acid, which means that it cannot be manufactured in the body. It is also well represented in all the proteins in the body. In vivo leucine kinetics presents a theoretically valid index of protein turnover. Consequently, isotopically labelled (2H, 3H, 13C, 14C or 15N) leucine is most commonly used for the study of protein metabolism in humans and animals (Fromm & Hargrove, 2012).
Amino acid involvement
1. Amino acid analysis
Leucine is an amino acid which is usually obtained by hydrolysis of most common proteins. It was among the first of amino acids to be discovered in 1819 in muscle fibre and wool (Bauman, et al., 1992). Leucine is present in large proportions in haemoglobin. This amino acid is also known for preventing the breakdown of muscle proteins caused by injury or stress (Lanpher, 2006). In addition, Leucine may be beneficial for people suffering from phenylketonuria. Leucine is an essential amino acid, so your body cannot produce it naturally but can only obtain it from food, including protein-rich animal food like fish, chicken, beef, also dairy and eggs.
Leucine is classified as a hydrophobic amino acid due to its aliphatic isobutyl side chain. It is encoded by six codons (UUA, UUG, CUU, CUC, CUA, and CUG) and is a major component of the subunits in ferritin, astacin and other ‘buffer’ proteins.
2. Inborn errors of the metabolism
Branched-chain organic acidurias are inborn errors of the metabolism involving the branched-chain amino acids (BCAAs) leucine, isoleucine and valine. These diseases usually involve neurological symptoms. They are treatable with strictly controlled diets and enhancement of detoxification of toxic intermediate metabolites. Detoxification is enhanced through supplementation of glycine, carnitine, biotin and other vitamins where applicable. The most common branched-chain organic acidurias are maple syrup urine disease (MSUD), 3-methylcrotonyl-CoA carboxylase (MCC), propionic aciduria (PCC), methylmalonic aciduria (MMA) and isovaleric aciduria (IVA) deficiency (Heidelberg, 2012).
Leucine is involved in a few inborn errors of the metabolism, from which maple syrup urine disease (MSUD) is one of the main mentioned. MSUD is caused by a deficiency in the branched-chain alpha-keto acid dehydrogenase complex. (Lanpher, 2006) Ketoacidosis, neurological disorders, and developmental disturbance can all be induced by the accumulations of branched-chain amino acids (BCAAs) and branched-chain alpha-keto-acids (BCKAs) in patients with MSUD. According to clinical investigations on MSUD patients, leucine levels over 400μmol/L apparently can cause any clinical problem derived from impaired function of the central nervous system. Damage to neuronal cells found in MSUD patients are presumably because of higher concentrations of both blood BCAAs or BCKAs, especially alpha-keto-isocapronic acids. These clinical data from MSUD patients provide a valuable basis on understanding leucine toxicity in the normal subject. (Fromm & Hargrove, 2012)
The complexity of the human genome and the metabolic reactions taking place in the human body results in many diseases having extremely variable phenotypes. This is the case with 3-methylcrotonyl-CoA carboxylase (MCC) deficiency (Baumgartner, 2004), an inborn error of leucine metabolism.
2. Cell transduction pathways
2.1 Leucine catabolism
Leucine is one of the three essential BCAAs. It plays vital roles in the regulation of protein synthesis and degradation (Shimomura, 2006). Leucine catabolism results in the formation of NADH (Nicotinamide adenine dinucleotide) and FADH (Flavin adenine dinucleotide), which can enter the oxidative phosphorylation reaction to provide ATPs. Exercise increases leucine catabolism greatly, to provide energy to muscle cells (Shimomura, 2006). To aid this process the enzymes responsible for leucine catabolism are closely associated with the mitochondrial membranes of muscle cell. The products shown in Figure 1 are acetyl-CoA and the ketone body aceto–acetic acid. Leucine is therefore known as a ketogenic amino acid. Acetoacetic acid can be converted to acetyl-CoA, which can then enter the Krebs cycle (Sweetman, n.d.).
Figure 1.1: Leucine catabolic pathway. This figure shows the intermediary metabolites of the leucine pathway. The enzymes involved in each step are shown on the left. (Adapted from Sweetman & Williams, 2001).
2.2 Leucine anabolism
Leucine has been proposed to be the primary mediator of the metabolic changes that occur when consuming a high protein diet. At the molecular level, leucine has been shown to activate the metabolic regulatory kinase known as mammalian target of rapamycin, mTOR. Activation of skeletal muscle mTOR results in increased protein synthesis and thus, increased energy expenditure. Hypothalamic mTOR activation is also involved in the regulation of feeding behaviors. Of note is the fact that direct injection of leucine into the hypothalamus results in increased mTOR signaling leading to decreased feeding behavior and body weight. This effect is unique to leucine, as direct injection of valine, another BCAA, does not result in hypothalamic mTOR activation nor reductions in food intake or body weight.
Macronutrients, such as protein or amino acid, not only supply calories but some components may also play as signaling molecules to affect feeding behavior, energy balance, and fuel efficiency. Leucine, a branched-chain amino acid is a good example. After structural roles are satisfied, the ability of leucine to function as signal and oxidative substrate is based on a sufficient intracellular concentration. Therefore, leucine level must be sufficiently high to play the signaling and metabolic roles. Leucine is not only a substrate for protein synthesis of skeletal muscle, but also plays more roles beyond that. Leucine activates signaling factor of mammalian target of rapamycin (mTOR) to promote protein synthesis in skeletal muscle and in adipose tissue. It is also a major regulator of the mTOR sensitive response of food intake to high protein diet. Meanwhile, leucine regulates blood glucose level by promoting gluconeogenesis and aids in the retention of lean mass in a hypocaloric state. It is beneficial to animal nutrition and clinical application and extrapolation to humans.
4. Multifactorial diseases
Genetic disorders may also be complex, multifactorial or polygenic; this means that they are likely associated with the effects of multiple genes in combination with lifestyle and environmental factors. Multifactorial disorders include heart disease anddiabetes. Although complex disorders often cluster in families, they do not have a clear-cut pattern of inheritance. This makes it difficult to determine a person’s risk of inheriting or passing on these disorders. Complex disorders are also difficult to study and treat because the specific factors that cause most of these disorders have not yet been identified.
1. Historical background of leucine analysis
Gas Chromatography – Mass spectrometry (GC-MS) has been extensively used to measure leucine enrichment in plasma samples in the past. Since leucine detectability threshold of a quadruple GC-MS was too low, a magnetic sector isotope sector ratio mass spectrometry (IRMS) was used. (Bauman, et al., 1992)This also had complications due to sample drying and the fact that it could only analyse gas samples. Hence, the labelled carboxyl group of leucine must be liberated as CO2 by means of a ninhydrin reaction for subsequent analysis by IRMS.
Another method is to use high performance liquid chromatography (HPLC) for the separation of amino acids. This involves separation by ion-exchange, with a gradient application of buffer and post-column derivatization to allow detection. (Bauman, et al., 1992) Non-derivative amino acids have been separated in reversed-phase columns with addition of an ion-pairing agent in the mobile phase. This is followed by post-column derivatization.
2. Current amino acid analysis types
Metabolomics is the study of the small molecules, contained in a cell, tissue, organ or biological fluid (Fromm & Hargrove, 2012). Metabolomics data can be generated from an array of sources such as liquid or gas chromatography coupled to mass spectrometry, capillary electrophoresis (CE), and nuclear magnetic resonance (NMR) spectroscopy (Corey D DeHaven*, 2012). Typically, metabolomics uses non-targeted methods where the analytical conditions are optimized to detect and identify as many molecules as possible. However, targeted metabolomics methods where the chromatography is optimized for detection of a specific molecule or class of molecules are also used. In either case, the structure of metabolomics data is generally three dimensional. For example, the data for a separation method coupled with mass spectrometry includes values for time, intensity and mass (m/z). The fundamental goal of metabolomics analysis is to quickly and accurately identify the metabolites detected in a complex biological sample and determine which change (increase or decrease) in response to experimental conditions (e.g., disease state, drug treatment, etc).
Urinary amino acid analysis is typically done by cation-exchange chromatography followed by postcolumn derivatization with ninhydrin and UV detection. This method lacks throughput and specificity. Two recently introduced stable isotope ratio mass spectrometric methods promise to overcome those shortcomings. Using two blinded sets of urine replicates and a certified amino acid standard, we compared the precision and accuracy of gas chromatography/mass spectrometry (GC–MS) and liquid chromatography–tandem mass spectrometry (LC–MS/MS) of propyl chloroformate and iTRAQ® derivatized amino acids, respectively, to conventional amino acid analysis. The GC–MS method builds on the direct derivatization of amino acids in diluted urine with propyl chloroformate, GC separation and mass spectrometric quantification of derivatives using stable isotope labeled standards. The LC–MS/MSmethod requires prior urinary protein precipitation followed by labeling of urinary and standard amino acids with iTRAQ® tags containing different cleavable reporter ions distinguishable by MS/MS fragmentation. Means and standard deviations of percent technical error (%TE) computed for 20 amino acids determined by amino acid analyzer, GC–MS, and iTRAQ®–LC–MS/MS analyses of 33 duplicate and triplicate urine specimens were 7.27±5.22, 21.18±10.94, and 18.34±14.67, respectively. Corresponding values for 13 amino acids determined in a second batch of 144 urine specimens measured in duplicate or triplicate were 8.39±5.35, 6.23±3.84, and 35.37±29.42. Both GC–MS and iTRAQ®–LC–MS/MS are suited for high through put amino acid analysis, with the former offering at present higher reproducibility andcompletely automated sample pretreatment, while the latter covers more amino acids and related amines.
3. Used method for leucine analysis
- Stabile isotope
- Column choice
- Mass spectrometry
The further development of derivatization reagents for plasma amino acid quantification by tandem mass spectrometry is described. The succinimide ester of 4-methylpiperazineacetic acid (MPAS), the iTRAQ reagent, was systematically modified to improve tandem mass spectrometer (MS/MS) product ion intensity. 4-Methylpiperazinebutyryl succinimide (MPBS) and dimethylaminobutyryl succinimide (DMABS) afforded one to two orders of magnitude greater MS/MS product ion signal intensity than the MPAS derivative for simple amino acids. CD(3) analogues of the modified derivatizing reagents were evaluated for preparation of amino acid isotope-labelled quantifying standards. Acceptable accuracy and precision was obtained with d(3)-DMABS as the amino acid standards derivatizing reagent. The product ion spectra of the DMABS amino acid derivatives are diagnostic for structural isomers including valine/norvaline, alanine/sarcosine and leucine/isoleucine. Improved analytical sensitivity and specificity afforded by these derivatives may help to establish liquid chromatography tandem mass spectrometry (LC-MS/MS) with derivatization generated isotope-labelled standards a viable alternative to amino acids analysers.
- Biological quantification
- Biological variance
- By using the optimal LC-MS conditions it is possible to obtain higher quality results in the analysis of leucine.
- Using optimal LC-MS conditions when analysing leucine, a decrease in the biological variance will be obtained.
- By decreasing the variation found in the experimental procedure of analysing leucine, a decrease in the biological variance will be obtained.
Bauman, P., Ebenstein, D. & O’Rourke, B., 1992. High-performance liquid chromatography technique for non-derivatized leucine purification: evidence for carbon isotope fractionantion. Jourmal of chromatography, Volume 573, pp. 11-16.
Baumgartner, M. e. a., 2004. Isolated 3-Methylcrotonyl-CoA Carboxylase Deficiency: Evidence for an Allele-Specific Dominant Negative Effect and Responsiveness to Biotin Therapy. American Journal of Human Genetics, pp. 790-800..
Burmeister, H., 2011. Genomic and metabolic investigation of an unknown inborn error of leucine metabolism mimicking MCC deficiency, Potchefstroom: North-West University.
Corey D DeHaven*, A. M. E. H. D. K. A. L., 2012. Organization of GC/MS and LC/MS metabolomics. Application News, Volume 432, pp. 13-33.
Fromm, H. J. & Hargrove, M. S., 2012. Essential Biochemistry. 1st ed. London New York: Springer Heidelberg Dordrecht.
Hannelore Kaspara, K. D. Q. C. S. D. S. N., 2009. Urinary amino acid analysis: A comparison of iTRAQ®–LC–MS/MS, GC–MS, and. Journal of Chromatography B, 877(32), pp. 4090-4096.
Heidelberg, S. D., 2012. Molecular Aspects of Iron. New York London: Springer Dordrecht Heidelberg New York London.
Lanpher, B. B.-p. N. &. L. B., 2006. Lanpher, B., Brunetti-Inborn errors of metabolism: the flux from Mendelian to complex diseases.. Nature Reviews: Genetics, Volume 7 June.
Shimomura, Y. e. a., 2006. Branched-Chain Amino Acids : Metabolism , Physiological Function , and Application Branched-Chain Amino Acid Catabolism in Exercise and Liver Disease 1 – 3. Public Health, pp. 250-253.
Sweetman, L. &. W. J., n.d. Branched Chain Organic Acidurias Valle et al.. Scriver’s OMMBID, pp. 1-81.
Cite This Work
To export a reference to this article please select a referencing stye below: